Artelo Biosciences issues $690K convertible notes and warrants to investors including directors

On October 28, 2025, Artelo Biosciences, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) pursuant to which it issued and sold to certain investors (the “ Investors ”), and the Investors purchased (by converting all or a portion of the unconverted “Voluntary Conversion” portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the “ Notes ”) to the Investors in an aggregate principal amount of $690,154.69;